Endometrial cancer is a malignant tumor that originates from the endometrium. The peak age of onset is 58-61 years old, but about 14% of endometrial cancers occur in women under 40 years old, and even in young women under 30 years old. In the past, the standard treatment for endometrial cancer was surgical removal of the entire uterus and bilateral adnexa, and the patient would be permanently deprived of the physiological function of reproduction. Conservative treatments such as high-dose progestin have now been shown to reverse the cancerous endometrium back to a normal lining. It offers a ray of hope for these patients to preserve their uterus, but not all women are suitable for treatment to preserve their reproductive function. A rigorous evaluation is required prior to treatment to meet the indications for conservative treatment. Patients will usually undergo a comprehensive examination, including blood sampling for liver and kidney lipids, Ca125, coagulation, fasting insulin level, ECG, chest X-ray, ultrasound, pelvic MRI, etc. Of course, the most important thing is the pathological examination and whether the pathological type is highly differentiated type I endometrial cancer, which is the most critical. Generally, the following conditions should be met before receiving conservative treatment for endometrial cancer 1, <40 years old 2, endometrioid adenocarcinoma 3, highly differentiated 4, immunohistochemistry suggesting positive progesterone estrogen receptor 5, no myometrial involvement in imaging 6, normal serum Ca125 level 7, no extra endometrial lesions 8, strong desire to preserve reproductive function 9, good compliance and follow-up conditions 10 If patients meet the above conditions, they can receive treatment to preserve their reproductive function, but we need to explain to them that such treatment is not standard treatment and requires their full understanding.